Max C. Gottlieb

Max C. Gottlieb is a West Virginia-based litigator with experience handling complex disputes, including patent infringement matters, often serving in a local counsel capacity. His patent litigation experience, as tracked, includes involvement in pharmaceutical and biologics cases, particularly those arising under the Biologics Price Competition and Innovation Act (BPCIA).

In his tracked patent appearances, Mr. Gottlieb served as Local Counsel in Regeneron Pharmaceuticals, Inc. v. Samsung Bioepis Co., Ltd. in the U.S. District Court for the Northern District of West Virginia. In this prominent litigation, which involved numerous patents related to Regeneron's EYLEA (aflibercept) product and Samsung Bioepis's proposed biosimilar, SB15, Mr. Gottlieb appeared on both the plaintiff and defendant sides. The case eventually resulted in a settlement allowing Samsung to launch its biosimilar product in the U.S. in January 2027.

Mr. Gottlieb is a Partner at Hissam · Forman · Donovan · Ritchie PLLC. His broader practice at the firm encompasses complex litigation and transactional matters, with a notable focus on the energy sector. He has also been involved in other significant cases, including a qui tam relator action against a healthcare system, a civil rights trial resulting in a successful jury verdict, and litigation against the DEA. There is no publicly available information indicating regular appearances by Mr. Gottlieb in PTAB or IPR proceedings.

Mr. Gottlieb is admitted to practice in West Virginia and before the U.S. Court of Appeals for the Fourth Circuit and the U.S. District Court for the Southern District of West Virginia. He earned his J.D., summa cum laude and Order of the Coif, from Washington and Lee School of Law, and his undergraduate degree in Government from Georgetown University. He previously served as a law clerk for Hon. Robert B. King of the U.S. Court of Appeals for the Fourth Circuit and Hon. Robert C. Chambers of the U.S. District Court for the Southern District of West Virginia.